Related Experiment Videos
Indium-111-pentetreotide in Graves' disease
1Department of Endocrinology/Metabolism, Gutenberg-University Hospital, Mainz, Germany.
Summary
Graves' disease imaging using pentetreotide shows reduced orbital accumulation after treatment. This radiotracer can help evaluate disease severity and treatment response in patients with Graves' ophthalmopathy.
Area of Science:
- Nuclear medicine
- Endocrinology
- Ophthalmology
Background:
- Graves' disease involves lymphocytic infiltration of the thyroid and orbit.
- Somatostatin receptors are present on lymphocytes, suggesting a role for receptor imaging.
- Pentetreotide, a somatostatin analog, is used for receptor imaging.
Purpose of the Study:
- To evaluate the utility of pentetreotide imaging in Graves' disease.
- To assess changes in pentetreotide uptake in the orbit and thyroid during treatment.
- To determine if initial imaging can predict treatment response.
Main Methods:
- 20 Graves' patients with active eye disease underwent SPECT and planar imaging with 111In-pentetreotide.
- Imaging was performed before and 3 months after initiating antithyroid drugs and combined steroid/radiotherapy.
- Orbital and thyroidal uptake of pentetreotide was quantified.
Main Results:
- Thyroidal uptake of pentetreotide decreased significantly with methimazole treatment.
- The orbit-to-brain ratio of pentetreotide uptake decreased markedly after therapy.
- A high pretreatment orbit-to-brain ratio predicted a positive response to steroid and radiotherapy.
Conclusions:
- Pentetreotide scans serve as a semiobjective tool for evaluating Graves' disease.
- Imaging can assess disease status at initial diagnosis and monitor treatment effectiveness.
- The findings support the use of pentetreotide imaging in managing Graves' ophthalmopathy.